Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1939]
News [3134]
Articles [127]
Editorials [3]
Conferences [119]
elearning [13]
The evolving landscape in the management of CML
Jan Geissler - Co-founder of CML Advocates Network, Prof Giuseppe Saglio...
The evolving landscape in the management of CML ( Jan Geissler - Co-founder of CML Advocates Network, Prof Giuseppe Saglio - University of Turin, Italy, Dr Delphine Rea - Saint Louis Hospital, France )
5 Jul 2012
Maintenance therapy in multiple myeloma; the way forward
Prof Gareth Morgan - The Royal Marsden Hospital, London, Prof Antonio Palumbo...
Maintenance therapy in multiple myeloma; the way forward ( Prof Gareth Morgan - The Royal Marsden Hospital, London, Prof Antonio Palumbo - University Hospital of Torino, Italy, Dr Paul Richardson - Dana-Farber Cancer Institute, USA )
4 Jul 2012
A new treatment paradigm in multiple myeloma
Prof Gareth Morgan - The Royal Marsden Hospital, London, Prof Antonio Palumbo...
A new treatment paradigm in multiple myeloma ( Prof Gareth Morgan - The Royal Marsden Hospital, London, Prof Antonio Palumbo - University Hospital of Torino, Italy, Dr Paul Richardson - Dana-Farber Cancer Institute, USA )
4 Jul 2012
Advances with bendamustine in multiple myeloma from EHA 2012
Prof Philippe Rodon - General Hospital, Blois, France
Advances with bendamustine in multiple myeloma from EHA 2012 ( Prof Philippe Rodon - General Hospital, Blois, France )
4 Jul 2012
Advances in multiple myeloma from EHA 2012
Prof Meletios Dimopoulos - Univeristy of Athens, Greece
Advances in multiple myeloma from EHA 2012 ( Prof Meletios Dimopoulos - Univeristy of Athens, Greece )
4 Jul 2012
Advances in multiple myeloma from EHA 2012; bortezomib and beyond
Prof Heinz Ludwig - Wilhelminenspital, Center for Oncology and Hematology...
Advances in multiple myeloma from EHA 2012; bortezomib and beyond ( Prof Heinz Ludwig - Wilhelminenspital, Center for Oncology and Hematology, Vienna, Austria )
4 Jul 2012
Dasatinib vs. imatinib first-line in CML; new study data
Prof Giuseppe Saglio - University of Turin, Italy
Dasatinib vs. imatinib first-line in CML; new study data ( Prof Giuseppe Saglio - University of Turin, Italy )
4 Jul 2012
The evolving landscape in CML management
Dr Delphine Rea - Saint Louis Hospital, Paris
The evolving landscape in CML management ( Dr Delphine Rea - Saint Louis Hospital, Paris )
4 Jul 2012
AZA in MDS, and managing the older MDS patient
Prof Valeria Santini – University of Florence, Italy
AZA in MDS, and managing the older MDS patient ( Prof Valeria Santini – University of Florence, Italy )
4 Jul 2012
Lenalidomide in low-risk MDS del(5q)
Prof Aristoteles Giagounidis - St. John’s Hospital, Duisburg, Germany
Lenalidomide in low-risk MDS del(5q) ( Prof Aristoteles Giagounidis - St. John’s Hospital, Duisburg, Germany )
4 Jul 2012
EHA 2012 advances in lymphoma; lenalidamide and beyond
Prof John Gribben - Barts & The London Trust Cancer Centre, UK; Prof Gilles...
EHA 2012 advances in lymphoma; lenalidamide and beyond ( Prof John Gribben - Barts & The London Trust Cancer Centre, UK; Prof Gilles Salles - Universite Claude Bernard, Lyon, France )
29 Jun 2012
Identifying drug sensitivity and resistance in acute myeloid leukaemia
Dr Mark Frattini – Memorial Sloan-Kettering Cancer Center, New York, USA
Identifying drug sensitivity and resistance in acute myeloid leukaemia ( Dr Mark Frattini – Memorial Sloan-Kettering Cancer Center, New York, USA )
27 Jun 2012

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation